scholarly journals The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled study

2011 ◽  
Vol 111 (9) ◽  
pp. 2261-2269 ◽  
Author(s):  
Shawn Portal ◽  
Zvi Zadik ◽  
Jonathan Rabinowitz ◽  
Ruty Pilz-Burstein ◽  
Dana Adler-Portal ◽  
...  
Keyword(s):  
Body Composition ◽  
Inflammatory Mediators ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Volleyball Players

scholarly journals Effect of Citrulline and Leucine Intake with Exercises on Body Composition, Physical Activity, and Amino Acid Concentration in Older Women: A Randomized Double-Blind Placebo-Controlled Study

Foods ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3117
Author(s):  
Mijin Kim ◽  
Hiroko Isoda ◽  
Tomohiro Okura
Keyword(s):  
Physical Activity ◽  
Body Composition ◽  
Body Weight ◽  
Amino Acid ◽  
Older Women ◽  
Body Mass ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Amino Acid Concentrations

The combined intake of citrulline (CIT) and leucine (LEU) can stimulate protein synthesis. Therefore, this study aimed to investigate the effect of combined intake of CIT and LEU accompanied by exercise for 20 weeks on body composition, physical activity (PA), and amino acid concentrations in older Japanese women with low body mass index (BMI) (16 to 21 kg/m2) using a randomized, double-blind, placebo-controlled design. The supplement was administered twice a day for 20 weeks (Ex (exercise) + CIT·LEU group, n = 10: mainly 0.8 g CIT and 1.6 g LEU; Ex + Placebo group, n = 13: mainly 3.5 g carbohydrate). Additionally, both groups exercised (weight-bearing exercise, square stepping exercise) once a week for 75 min. Body composition, PA, and amino acid concentrations in the plasma were measured. Body weight, BMI, body mass, household PA, total PA, and phenylalanine significantly increased in the Ex + CIT·LEU group (p < 0.05) post intervention. This study suggests that the combined intake of CIT and LEU accompanied by exercise can improve body weight, BMI, body mass, and PA in older women with low BMI, which may prevent sarcopenia and frailty.

scholarly journals A randomized, double-blind, placebo-controlled study of liraglutide 3 mg [LIRA 3mg] on weight, body composition, hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome (PCOS)

2021 ◽  
Author(s):  
Karen Elkind-Hirsch ◽  
Neil Chappell ◽  
Donna Shaler ◽  
John Storment ◽  
Drake Bellanger
Keyword(s):  
Body Composition ◽  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Change In Mean

Abstract BackgroundThe efficacy of lifestyle modifications for established obesity is limited in women with polycystic ovary syndrome (PCOS) and more aggressive interventions are needed. We assessed the efficacy and safety of the GLP-1 analogue liraglutide 3mg (LIRA 3mg) versus placebo (PL) for reduction of body weight and hyperandrogenism in women with obesity and PCOSMethodsThis randomized, double-blind, placebo-controlled study enrolled women from a single-outpatient center diagnosed with PCOS (NIH criteria) with a body-mass index of at least 30 kg/m.2 Participants were randomly allocated (2:1) to treatment with a subcutaneous injection LIRA 3mg or visually matching placebo, once daily for 32 weeks, plus lifestyle intervention. Study visits at baseline, and 32 weeks included weight, blood pressure (BP), waist (WC) measures and body composition evaluated by dual-energy X-ray absorptiometry (DXA). Oral glucose tolerance tests (OGTT) were done to assess glycemia, mean blood glucose (MBG), and compute insulin sensitivity (SI) and secretion (IS) measures. Sex steroids, free androgen index (FAI), complete metabolic profile and lipid profiles were measured in the fasting sample. Co-primary endpoints were change in body weight (BW) and FAI. Safety was assessed in all patients who received at least one dose of study drug. This study was registered with ClinicalTrials.gov NCT03480022FindingsFrom October 2018 to June 2020, 88 patients were screened, of whom 82 were randomly assigned to LIRA 3mg (n = 55) or PL (n = 27). Change in mean BW from baseline to week 32 was − 5.7% (SE 0·.75) with LIRA 3mg vs. -1.4% (1.09) with PL (P < 0.002). At week 32, more patients on LIRA 3 mg than on placebo achieved weight reductions of at least 5% (25[57%] of 44 vs. 5 [22%] of 23; (p < 0·007). LIRA 3mg resulted in significant reduction of FAI, improvements in SI and IS as well as OGTT MBG, and improved body fat by DXA. Gastrointestinal adverse events, which were mostly mild to moderate, were reported in 32 (58.2%) of 55 patients with LIRA 3mg, and 5 (18.5%) of 27 with PL.InterpretationIn obese women with PCOS, LIRA 3mg once daily achieved a superior and clinically meaningful decrease in BW and androgenicity and improved cardiometabolic parameters compared with placebo.

scholarly journals Clinical Evaluation on Digestive and Metabolic Parameters of a Prodosomed Enzyme Formulation, N-SORB: A Randomized, Double-Blind, Placebo-Controlled Study

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 737-737
Author(s):  
Debasis Bagchi ◽  
Sreejayan Nair ◽  
Derek Smith ◽  
Rama Nair ◽  
Berrnard Downs ◽  
...  
Keyword(s):  
Body Composition ◽  
Sleep Quality ◽  
Physical Health ◽  
Lipid Profile ◽  
Case Studies ◽  
Sleep Pattern ◽  
Whole Body ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Objectives Optimal nutrition and natural digestive enzymes play a critical role in enhancing healthy digestion. N-SORB, a novel KD120 liquid multienzyme complex was developed and encapsulated using a SK713 SLP absorption technology (Prodosome®). A randomized, double-blind placebo-controlled investigation over a period of 90 consecutive days was conducted to determine the safety and efficacy of N-SORB on diverse parameters of the blood, immune health and physical health. Methods Forty-six (age: 25.8 ± 12.1 years) healthy volunteers received either N-SORB or placebo for 90 consecutive days. Complete blood count, as well as blood glucose, liver enzymes, and lipid profile were assessed pre- and post-intervention. Serum cytokine levels were determined using ELISA. Whole Body composition analysis was performed by DEXA to determine body fat mass, lean mass and android and gynoid fat. Body weight, blood pressure, and physical health were assessed. Changes in quality of life (QOL) were examined using WHOQOL-BREF questionnaire. Sleep quality was assessed using Pittsburgh Sleep Quality Index (PSQI) questionnaire. Adverse events were monitored. This clinical investigation was followed by three case studies. Results 40 subjects completed the study. Compared to placebo, changes in blood cell counts including hematocrit, hemoglobin, mean corpuscular volume, platelets and lymphocytes provide evidence indicating consistent trends of improvement. QOL parameters showed significant improvement in N-SORB group. A significant increase was observed in AST level in the placebo group, while, no increase was observed in the N-SORB group. In either group, no significant changes in BUN, serum creatinine, ALP, ALT, and lipid profile were observed. No adverse effects were reported. Case study volunteers also reported encouraging results. Conclusions N-SORB exhibited trends of improvement in some RBC and immune parameters and found improvements in QOL and PSQI; but didn't significantly alter cardiometabolic parameters, lipid profile or body composition. N-SORB induced significant improvement in digestive health, metabolism and sleep pattern. Case studies indicated significant improvement in digestion, sleep pattern and metabolic health. Funding Sources This Project was funded by VNI Inc, Lederach, PA.

Sign in / Sign up

Export Citation Format

Share Document